The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Nov 2019
Clinical TrialLong-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Mepolizumab is approved for patients with severe asthma with an eosinophilic phenotype aged 12 or more (United States) or 6 or more (European Union) years, but its long-term use in children aged 6 to 11 years has not yet been assessed. ⋯ Long-term safety, pharmacodynamic, and efficacy data from this study support a positive benefit-risk profile for mepolizumab in children with severe asthma with an eosinophilic phenotype and were similar to data in studies in adults and adolescents.